•  
  •  
 

Corresponding Author

Mohammad Shahid Iqbal, Department of Pathology, Medicine Program, Batterjee Medical College, 21442 Jeddah, Saudi Arabia

Authors ORCID

0000-0001-6683-409X

Document Type

Original Article

Abstract

Background: Breast cancer in women is the most frequently diagnosed and lethal form of the disease. A woman's operable invasive breast cancer's hormone receptor subtype is a major long-term prognostic predictor.

Objectives: To investigate the expression of ER, PR, and Her-2/neu in invasive breast cancer and how it relates to clinicopathological prognostic variables.

Materials and Methods: This study examines all invasive breast cancer patients who were seen between 2019 and 2020 at King Khalid Hospital in Najran. From the laboratory records, the demographic and clinical information, microscopic features, histological grade, lymph node metastases, stage, and final diagnosis, including immunohistochemical results for ER, PR, and Her2/neu expression, were taken and analyzed in accordance with the goals.

Results: Breast cancer type luminal A was the most common. There was a greater prevalence of luminal A type (ER/PR+, Her-2/neu-negative) in older patients compared to the triple negative and Her 2+ subtypes in younger patients. Invasive ductal carcinoma was the most prevalent histopathological type. There was no statistical link between ER, PR, and Her2/neu receptor expression and any of the breast cancer histological subtypes. The Her2+ subtype had the highest percentage of grade III lesions, followed by the triple negative subtype. Luminal types A and B were the most common in grade I tumors.

Conclusion: In women with operable invasive breast cancer, the hormone receptor subtype is a significant independent prognostic predictor. Proper diagnosis requires regular testing of steroid hormone receptor and Her- 2/neu expression.

Keywords

Breast cancer; Estrogen receptor; Progesterone receptor

Subject Area

Pathology

Download

Share

COinS